Email this article 
Post a Comment Topical administration of Oftaquix® and Tobrex® in refractive surgery
- Authors: Kachanov A.B.1, Pavlova Y.A.1, Vokhmyakov A.V.2
-
Affiliations:
- S.N. Fyodorov Microsurgery Complex
- Santen Oy Representation in Moscow
- Issue: Vol 6, No 2 (2013)
- Pages: 55-59
- Section: Articles
- URL: https://journal-vniispk.ru/ov/article/view/402
- DOI: https://doi.org/10.17816/OV2013255-59
- ID: 402
Cite item
Full Text
Abstract
Background: Due to the growing resistance of causative microorganisms to previous generations of antibiotics and to the risk of post-op infectious complications associated with it, an efficacy and safety assessment of modern fluoroquinolones’ prophylactic topical administration appears to be reasonable. Purpose: To investigate the efficacy and safety of levofloxacin 0.5 % ophthalmic solution (Oftaquix®, Santen, Finland) topical use in modern excimer laser refractive surgery (LASIK). Material and methods: Patients were randomized into two treatment groups: Thirty two patients (64 eyes) were treated with levofloxacin 0.5 % ophthalmic solution (Oftaquix®, Santen, Finland) b.i.d. and thirty patients (60 eyes) received tobramycine 0.3 % eye drops (Tobrex®, Alcon-Couvreur, Belgium) q. t.d., both during first 7 days post-op. LASIK procedure using excimer laser MEL-80 (Carl Zeiss Meditec, Germany) and mechanical microkeratome LSK Moria Evolution-2 (Moria, France) was performed in all patients for myopia from –1.0 to –12.0 D. Patient’s age varied from 18 to 40 years (mean age 28.4±7.8). Results: During topical application of Oftaquix® and Tobrex® in our refractive surgery patients there were no topical, or systemic adverse reactions, or allergic reactions. Oftaquix® and Tobrex® had good topical tolerability. Therapeutic dosage regimen, sufficient in terms of anti-infective prophylaxis, in case of Oftaquix® was twice as low in comparison to Tobrex®. Tear film break-up time (TFBUT) preand post-op was comparable between groups. In both groups, TFBUT post-op was significantly lower compared to pre-op values (p < 0.01). Tear production (Shirmer-I test) in both groups remained almost the same (p > 0.05). Conclusion: Oftaquix® (Santen, Finland) ophthalmic solution is effective and safe for prevention of infectious complications after LASIK and appears to be a rational alternative to tobramycine 0.3 % eye drops (Tobrex®, Alcon-Couvreur, Belgium).
Keywords
About the authors
Andrey Borisovich Kachanov
S.N. Fyodorov Microsurgery Complex
Email: andrey_kachanov@yahoo.com
ophthalmologist, Candidate of Medical Science
Yulia Alexandrovna Pavlova
S.N. Fyodorov Microsurgery ComplexMD, ophthalmologist
Alexander Vladimirovich Vokhmyakov
Santen Oy Representation in MoscowMD, ophthalmologist, scientific adviser
References
- Балашевич Л. И., Качанов А. Б. Клиническая корнеотопография и аберрометрия. — М.: 2008. — 167 с., ил.
- Саркисян К. А., Вохмяков А. В. Профилактика инфекционных и воспалительных осложнений после ЛАЗИК // Офтальмологические ведомости. — 2009. — Т. 2, № 3. — С. 17–22.
- Юсеф Ю. Н., Школяренко Н. Ю., Аладинская И. В. и др. Офтаквикс при факоэмульсификации катаракты//Вестник офтальмологии. — 2012. — Т. 128, № 6. — С. 54–56.
- Izdebska J., Szaflik J. P. Levofloxacin (oftaquix) a fluoroquinolone of a new generation in prevention of the postoperative endophthalmitis following uncomplicated cataract surgery — the study of the European Society of Cataract and Refractive Surgeons (ESCRS) // Klin. Oczna. — 2005. — Vol. 107, № 4–6. — P. 344–347.
- Keating G. M. Levofloxacin 0.5 % ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery // Drugs. — 2009. — Vol. 18; (69) № 9. — P. 1267–1286.
Supplementary files
